Last reviewed · How we verify
single dose of CNCT19
At a glance
| Generic name | single dose of CNCT19 |
|---|---|
| Sponsor | Juventas Cell Therapy Ltd. |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study of CNCT19 in the Treatment of Relapsed or Refractory Neurological Autoimmune Diseases (EARLY_PHASE1)
- A Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric) (PHASE1, PHASE2)
- Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia (PHASE2)
- Inaticabtagene Autoleucel (Inati-cel; CNCT19) Treatment for MRD-Positive B-ALL Patients in CR1 (PHASE2)
- CNCT19 Following ASCT in Patients With Relapsed or Refractory B-cell Lymphoma (PHASE1, PHASE2)
- Exploratory Clinical Study of CNCT19 Anti CD19 Cell Therapy in the Treatment of Refractory Autoimmune Diseases (EARLY_PHASE1)
- Phase II Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma (PHASE2)
- Inaticabtagene Autoleucel (Inati-cel; CNCT19) Treatment for Newly Diagnosed B-cell ALL Patients in CR1 (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- single dose of CNCT19 CI brief — competitive landscape report
- single dose of CNCT19 updates RSS · CI watch RSS
- Juventas Cell Therapy Ltd. portfolio CI